| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
5 companies
Timothy M Shannon last filed a Form 4 in June 2023, as Director at CTMX. The filings on record cover 5 companies. Timothy M Shannon's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Timothy M Shannon's trades have earned a strong insider score of 82/100 across 12 rated trades. Over a 12-month horizon, 91.7% of those trades were profitable, with an average 12-month return of +40.4%.
At the last filing, the largest reported position was 2,660,713 shares of IDYA. Net of sales, the IDYA filings show accumulation of 400,000 shares.
Timothy M Shannon has 40 Form 4 filings on record from October 2015 to June 2023, across 5 companies: Director at IDEAYA Biosciences (IDYA), 2019–2023; Director at Arvinas (ARVN), 2018–2022; Director at Rallybio (RLYB), 2021–2022, and 2 more.
The 89 reported transactions were 54 open-market sales, 13 option or other derivative awards, 9 conversions and 8 open-market purchases, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 8 purchases worth about $6.1M and 19 sales worth about $41.4M.
The largest open-market purchase was 400,000 shares of IDYA at an average $10.00 on May 28, 2019, about $4.0M.
The largest open-market sale was 190,557 shares of ARVN at an average $86.25 on September 2, 2021, about $16.4M. Twelve months later ARVN was down 50%.
Shares as reported in the last Form 4 for each company; the most recent is from June 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 7, 2021 | ARVN Arvinas, Inc. | Director | Sell | 68,798 | $87.41 | $6,013,941.78 | -4.0% | -15.8% | -49.5% | |
| Sep 2, 2021 | ARVN Arvinas, Inc. | Director | Sell | 190,557 | $86.25 | $16,436,487.73 | -10.0% | -12.4% | -50.2% | |
| Aug 30, 2021 | ARVN Arvinas, Inc. | Director | Sell | 115,576 | $85.72 | $9,907,378.57 | -5.7% | -11.0% | -50.9% | |
| Aug 25, 2021 | ARVN Arvinas, Inc. | Director | Sell | 25,069 | $85.95 | $2,154,690.44 | -1.2% | -2.9% | -44.9% | |
| Aug 2, 2021 | RLYB Rallybio Corp | Director | Buy | 76,923 | $13.00 | $999,999.00 | +3.3% | +1.1% | -48.4% | |
| Jun 17, 2020 | ARVN Arvinas, Inc. | Director | Buy | 2,000 | $30.26 | $60,519.80 | +2.6% | - | - | |
| Jun 2, 2020 | ARVN Arvinas, Inc. | Director | Buy | 3,000 | $32.30 | $96,900.00 | +4.0% | - | - | |
| Mar 20, 2020 | ARVN Arvinas, Inc. | Director | Buy | 2,500 | $40.00 | $100,000.00 | +4.2% | - | - | |
| May 28, 2019 | IDYA Ideaya Biosciences, Inc. | Director | Buy | 400,000 | $10.00 | $4,000,000.00 | +17.7% | - | - | |
| May 13, 2019 | NXTC Nextcure, Inc. | Director | Buy | 50,000 | $15.00 | $750,000.00 | +2.3% | - | - |